Huntington's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Huntington's Disease, including details on genetics, causes, symptoms, treatment.

Volume 1 (2005), Issue 9 (September)

1. Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing.
   Neurobiol Dis, 20(1): 1-11. [Abstract] [Full-text]
2. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats.
   Brain Res Bull, 67(1): 161-8. [Abstract] [Full-text]
3. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.
   J Comp Neurol, 490(4): 354-70. [Abstract] [Full-text]
4. Sensorimotor mapping affects movement correction deficits in early Huntington's disease.
   Exp Brain Res, 165(4): 454-60. [Abstract] [Full-text]
5. Synaptic dysfunction in Huntington's disease: a new perspective.
   Cell Mol Life Sci, 62(17): 1901-12. [Abstract] [Full-text]
6. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition.
   Neurology, 65(5): 745-7. [Abstract] [Full-text]
7. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.
   Hum Mol Genet, 14(19): 2871-80. [Abstract] [Full-text]
8. Characterization of a possible amyloidogenic precursor in glutamine-repeat neurodegenerative diseases.
   Proc Natl Acad Sci U S A, 102(38): 13433-8. [Abstract] [Full-text]
9. A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington's disease.
   J Neuropsychiatry Clin Neurosci, 17(3): 378-83. [Abstract] [Full-text]
10. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.
    J Neurochem, 95(1): 210-20. [Abstract] [Full-text]
11. Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers.
    J Neurochem, 95(1): 125-36. [Abstract] [Full-text]
12. Firing rates of pallidal neurons are similar in Huntington's and Parkinson's disease patients.
    Exp Brain Res, 166(2): 230-6. [Abstract] [Full-text]
13. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents.
    Exp Brain Res, 166(2): 220-9. [Abstract] [Full-text]
14. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease.
    Eur J Neurosci, 22(6): 1541-6. [Abstract] [Full-text]
15. Avoidance as a strategy of (not) coping: qualitative interviews with carers of Huntington's Disease patients.
    BMC Fam Pract, 6: 38. [Abstract] [Full-text]
16. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.
    J Neurochem, 95(2): 553-62. [Abstract] [Full-text]

© 2005-2008 Huntington's Disease Research Today. All Rights Reserved.